| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T329 |
0-247 |
Sentence |
denotes |
There are several pharmacological studies suggesting molecular targets for the anti-inflammatory effects of n-3 PUFAs and their metabolites: PPAR-γ, GPR120, CMKLR1 (known as ChemR23), BLT1(leukotriene B4 receptor 1), GPR32 and ALX/FPR2 (Im, 2012). |
| T330 |
248-345 |
Sentence |
denotes |
Thus, resolvins E1 and D1 exhibited a higher affinity for these receptors compared to EPA or DHA. |
| T331 |
346-474 |
Sentence |
denotes |
Chem R23 and BLT1 are receptors of resolvin E1, while GPR32 and ALX/FPR2, bind to lipoxin A4 and resolvin D1 with high affinity. |
| T332 |
475-615 |
Sentence |
denotes |
GPR120 was reported to be a receptor of EPA and DHA (EC50 ~ 1–10 μM), while ALX/FPR2 to annexin I and lipoxin A4 (Serhan and Petasis, 2011). |
| T333 |
616-828 |
Sentence |
denotes |
Furthermore, some studies on GPR120 KO mice suggest that n-3 PUFAs that activate GPR120, interact with β-arrestin 2, and suppress NF-κB activation and macrophage-mediated inflammatory responses (Oh et al., 2010). |
| T334 |
829-1093 |
Sentence |
denotes |
However, it is important to highlight that the in vivo anti-inflammatory effects of n-3 PUFAs in humans are minor and might only occur at high n-3 PUFA levels, it was demonstrated in vitro that BSA-conjugated n-3 PUFA are incapable of activating GPR120 (Im, 2012). |
